Evidence map›Paper›PMID 24722190›Full record

ArticlePloS one2014

Red blood cell distribution width and long-term outcome in patients undergoing percutaneous coronary intervention in the drug-eluting stenting era: a two-year cohort study.

Hai-Mu Yao, Tong-Wen Sun, Xiao-Juan Zhang, De-Liang Shen, You-You Du, You-Dong Wan, Jin-Ying Zhang, Ling Li, Luo-Sha Zhao

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 18 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
4 · The record

Corrections and comments

  • Erratum issued
5 · Who and what money

Authors and funding

9 authors.

Hai-Mu YaoDepartment of Cardiology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, P. R. China.
Tong-Wen SunDepartment of Integrated ICU, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, P. R. China.
Xiao-Juan ZhangDepartment of Integrated ICU, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, P. R. China.
De-Liang ShenDepartment of Cardiology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, P. R. China.
You-You DuDepartment of Cardiology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, P. R. China.
You-Dong WanDepartment of Integrated ICU, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, P. R. China.
Jin-Ying ZhangDepartment of Cardiology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, P. R. China.
Ling LiDepartment of Cardiology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, P. R. China.
Luo-Sha ZhaoDepartment of Cardiology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, P. R. China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPrevious studies suggest the higher the red blood cell distribution width (RDW) the greater the risk of mortality in patients with coronary artery disease (CAD). However, the relationship between RDW and long-term outcome in CAD patients undergoing percutaneous coronary intervention (PCI) with a drug-eluting stent (DES) remains unclear. This study was designed to evaluate the long-term effect of RDW in patients treated with drug-eluting stent for CAD.

methodsIn total of 2169 non-anemic patients (1468 men, mean age 60.2 ± 10.9 years) with CAD who had undergone successful PCI and had at least one drug-eluting stent were included in this study. Patients were grouped according to their baseline RDW: Quartile 1 (RDW<12.27%), Quartile 2 (12.27% ≤ RDW <13%), Quartile 3 (13% ≤ RDW<13.5%), and Quartile 4 (RDW ≥ 13.5).

resultsThe incidence of in-hospital mortality and death or myocardial infarction was significantly higher in Quartiles 3 and 4 compared with Quartile 1 (P<0.05). After a follow-up of 29 months, the incidence of all-cause death and stent thrombosis in Quartile 4 was higher than in Quartiles 1, 2, and 3 (P<0.05). The incidence of death/myocardial infarction/stroke and cardiac death in Quartile 4 was higher than in Quartiles 1 and 2 (P<0.05). Multivariate Cox regression analysis showed that RDW was an independent predictor of all-cause death (hazard ratio (HR) = 1.37, 95% confidence interval (CI) = 1.15-1.62, P<0.001) and outcomes of death/myocardial infarction/stroke (HR = 1.21, 95% CI = 1.04-1.39, P = 0.013). The cumulative survival rate of Quartile 4 was lower than that of Quartiles 1, 2, and 3 (P<0.05).

conclusionHigh RDW is an independent predictor of long-term adverse clinical outcomes in non-anemic patients with CAD treated with DES.

Indexed as

Drug-Eluting StentsErythrocytesAgedCohort StudiesCoronary Artery DiseaseErythrocyte IndicesFemaleHospital MortalityHumansMaleMiddle AgedPercutaneous Coronary InterventionPrognosisRegistriesRisk FactorsSurvival Rate

Identifiers

PMID24722190
PMCPMC3983260

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.